AUSTRALIA Patents Act COMPLETE SPECIFICATION (ORIGINAL) Class Int. Class Application Number: Lodged: Complete Specification Lodged: Accepted: Published: Priority Related Art: Name of Applicant: The Gillette Company Actual Inventor(s): Cheng Shine Hwang Address for Service and Correspondence: PHILLIPS ORMONDE FITZPATRICK Patent and Trade Mark Attorneys 367 Collins Street Melbourne 3000 AUSTRALIA Invention Title: REDUCTION OF HAIR GROWTH Our Ref: 923469 POF Code: 103357/228894 The following statement is a full description of this invention, including the best method of performing it known to applicant(s): Boomq -lA REDUCTION OF HAIR GROWTH The present application is a divisional from Australian Application No 2006252877, the entire disclosure of which is incorporated herein by reference. The invention relates to reducing hair growth in mammals, particularly for 5 cosmetic purposes. A main function of mammalian hair is to provide environmental protection. However, that function has largely been lost in humans, in whom hair is kept or removed from various parts of the body essentially for cosmetic reasons. For example, it is generally preferred to have hair on the scalp but not on the face. 10 Various procedures have been employed to remove unwanted hair, including shaving, electrolysis, depilatory creams or lotions, waxing, plucking, and therapeutic antiandrogens. These conventional procedures generally have drawbacks associated with them. Shaving, for instance, can cause nicks and cuts, and can leave a perception of an increase in the rate of hair regrowth. Shaving also can leave an undesirable stubble. 15 Electrolysis, on the other hand, can keep a treated area free of hair for prolonged periods of time, but can be expensive, painful, and sometimes leaves scarring. Depilatory creams, though very effective, typically are not recommended for frequent use due to their high irritancy potential. Waxing and plucking can cause pain, discomfort, and poor removal of short hair. Finally, antiandrogens -- which have been used to treat female hirsutism -- can have unwanted 20 side effects. It has previously been disclosed that the rate and character of hair growth can be altered by applying to the skin inhibitors of certain enzymes. These inhibitors include inhibitors of 5-alpha reductase (see, for example, Breuer et al., U.S. Pat. No. 4,885,289); ornithine decarboxylase (see, for example, Shander, U.S. Pat. No. 4,720,489), 25 S-adenosylmethionine decarboxylase (see, for example Shander, U.S. patent 5,132,293); adenylosuccinate synthase (see, for example, Ahluwalia); U.S. Pat. No. 5,095,007); aspartate transcarbamylase (see, for example, Ahluwalia, U.S. Pat. No. 5,095,007); gamma-glutamyl transpeptidase (see, for example, Ahluwalia et al., U.S. Pat. No. 5,096,911); transglutaminase (see, for example, Shander, et al., U.S. Patent 5,143,925); L-asparagine synthetase 30 (see, for example, Ahluwalia, U.S. Patent 5,444,090); 5-lipoxygenase (see, for example, Ahluwalia et al., U.S. Patent 6,239,170); cyclooxygenase (see, for example, Ahluwalia et al., U.S. Patent 6,248,751); nitric oxide SPECI (DIV)_Amended pages & claims)_923469_BDJ_22.08.2011 WO 2006/130330 PCT/US2006/018663 -2 synthase (see, for example Ahluwalia et al., U.S. Patent 5,468,476); ornithine aminotransferse (see, for example, Shander et al.,U.S. Patent 5,474,763); cysteine synthetic pathway enzymes including L-methionine S-adenosyltransferase. L-homocysteine S-methyl transferase, S-adenosyl homocysteine hydrolyase, cystathionine 5 synthase and cystathionase (see, for example, Ahluwalia et al., U.S. Patent 5,455,234); cholesterol synthesis pathway enzymes including IMGCoA reductase and squalene synthetase (see, for example, Henry et al., U.S. Patent 5840752); protein kinase C (see, for example, Ahluwalia et al.,U.S. Patent 5,554,608); arginase (see, for example, Shander et al., U.S. Patent 5,728,736); matrix metalloproteinase (see for example Styczynski et al., 10 U.S. Patent 5,962,466); DNA topoisomerase (see, for example Styczynski et al., U.S. Patent 6,037,326); aminoacyl-tRNA synthetase (see, for example, Henry et al., U.S. Patent 5,939,458); hypusine biosynthetic pathway enzymes including deoxyhypusine synthase and deoxyhypusine hydroxylase (see, for example, Styczynski et al. U.S. Patent 6,060,471); alkaline phosphatase (see, for example Styczynski et al., U.S. Patent 15 6,020,006); and protein-tyrosine kinase (see, for example Henry et al., U.S. Patent 6,121,269). U.S. Patent 5,908,867 (Henry et al.) describes a method for reducing mammalian hair growth by inhibiting the formation of glycoproteins, proteglycans or glycosaminoglycans, for example by use of inhibitors of the synthesis of N-acetyl 20 glucosamine-pyrophosphoryl-dolichyl, chondrotin sulfate, keratin sulfate, dermatan sulfate, heparan sulfate, heparin, hyaluronic acid, inhibitors of the formation of Glc 3 Man-(GlcNAc) 2 -PP-dolichol or glycosaminoglycan hyaluronic acid, inhibitors of the transfer of GlcMan-(GlcNAc) 2 , inhibitors of the enzymes glucosidase I, glucosidase II, mannosidas I, mannosidase II, and p-galactosidase and compounds that affect the 25 exocytosis of proteoglycans. U.S. Patents 5,652,273, 5,824,665 and 6,218,435 (all issued to Henry et al.) describe ways of reducing mammalian hair growth by suppression of the metabolic pathway for conversion of glucose to acetyl-Co-A. This can be effected by, inter alia, inhibition of hexokinase, phosphofructokinase, aldolase, phosphoglycerate kinase, 30 enolase, pyruvate kinase or pyruvate dehydrogenase or by an inhibitor of glucose transport.
WO 2006/130330 PCT/US2006/018663 -3 Other methods for modulating hair growth include use of compounds that induce or activates conjugation of an androgen, for example as described by Styczynski et al., in U.S. Patent 5,958,946; use of compounds to increase cellular ceramide levels for example as described by Styczynski et al., in U.S. Patent 6,235,737; use of non-steroidal 5 suppressors of angiogenesis, for example as described in Ahluwalia in U.S. Patent 6,093,748; use of catechin compounds, for example as described in U.S. Patents 5,674,477 and 5,776,442 (Abluwalia); use of sulfhydryl reactive compounds for example as described in Shander et al. In U.S. Patent 5,411,991; and use of pantothenic acid or an analogue thereof, for example as described by Ahluwalia et al in U.S. Patent 5,364,885. 10 PCT Publication W003086331 (Abluwalia et al) discloses that mammalian hair growth can be reduced by topical application of an inhibitor of fatty acid metabolism. PCT Publication WO 2005/051335 (Hwang et al.) describes the use of an agonist of a prostaglandin DP receptor for reduction of hair growth. Farnesoid X receptor (also known as "FXR", "RIP 14", "bile acid receptor", is "BAR", "HRRl" and "NRIH4") is a member of the family of ligand-activated transcription factors that bind to specific cis-acting regulatory elements in the promoters of their target genes and modulate gene expression in response to ligands. Some of these receptors bind to their target genes as dimers consisting of two molecules of the same receptor (homodimers), while others bind to as dimers consisting of one molecule each of 20 two different receptors (heterodimers). Famesoid X receptor forms a heterodimer with the retinoid X receptor (RXR) and binds to an inverted hexanucleotides repeat spaced by one nucleotide in the promoters of its target genes. Farnesoid X receptor is activated through interaction with ligands such as famesoids and bile acids. In addition, coactivators (DRIP205/TRAP220, SRC-1 and PGC-lalpha) that bridge between the 25 ligand-activated farnesoid X receptors and the basal transcription machinery, and /or influence the chromatin structure, can enhance the transcriptional activity of farnesoid X receptor. Farnesoid X receptor helps maintain bile acid homeostasis by modulating the expression of genes involved in the synthesis and transport of bile acid. Bile acids are 30 the end product of cholesterol catabolism. Synthesis of bile acid is the predominant mechanisms for the excretion of excess cholesterol. Most bile acids in human are -4 chenodeoxycholic acid, cholic acid, deoxycholic acid, ursodeoxycholic acid and lithocholic acid. While the level of bile acids is increased, farnesoid X receptor is activated and upregulates the expression of the bile salt export pump that is responsible for bile acid excretion. In addition to bile acid excretion, bile acid-activated farnesoid X receptor represses 5 the transcription of cholesterol 7alpha-hydroxylase (CYP7A1), which the rate-limiting enzyme in the bile acid biosynthesis pathway. The discussion of documents, acts, materials, devices, articles and the like is included in this specification solely for the purpose of providing a context for the present invention. It is not suggested or represented that any or all of these matters formed part of the 10 prior art base or were common general knowledge in the field relevant to the present invention as it existed before the priority date of each claim of this application. Where the terms "comprise", "comprises", "comprised" or "comprising" are used in this specification (including the claims) they are to be interpreted as specifying the presence of the stated features, integers, steps or components, but not precluding the presence of one or 15 more other features, integers, steps or components, or group thereof. In one aspect, the invention provides a method (typically a cosmetic method) of reducing unwanted mammalian (preferably human) hair growth by applying to the skin an agonist of farnesoid X receptor in an amount effective to reduce hair growth. Preferably, the agonist interacts strongly with the farnesoid X receptor. The unwanted hair growth may be 20 undesirable from a cosmetic standpoint. In another aspect the invention provides a cosmetic method of reducing mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and applying to said area of skin a dermatologically acceptable composition comprising an agonist of farnesoid X receptor in an amount effective to reduce hair growth, 25 wherein said agonist is not a carbamate or ester of a-difluoromethylomithine and is not ursodeoxycholic acid. In another aspect the invention provides a cosmetic method of reducing mammalian hair growth which comprises selecting an area of skin from which reduced hair growth is desired; and 30 applying to said area of skin a dermatologically acceptable composition comprising an agonist of farnesoid X receptor in an amount effective to reduce hair growth, wherein said agonist is selected from the group consisting of: SPEC! (DIV)_Amended pages & caims)_923469_BDJ_22.08.2011 - 4A (i) 7-methyl-9-(3,3- dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid methyl ester (juvenile hormone III); (ii) 7-methyl-9-(3,3- dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid ethyl ester; (iii) benzenesulfonamide, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1 5 (trifluoromethyl)ethyl] phenyl]-; (iv) benzoic acid, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(1-methylethyl)-4 isoxazolyl]methoxy]phenyl]ethenyl]-; (v) phosphonic acid, [[3,5-bis(l,l-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, tetraethyl ester; 10 (vi) phosphonic acid, [2-[3,5-bis(l,l-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetrakis(l-methylethyl) ester; (vii) phosphonic acid, [2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetraethyl ester; and (viii) phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, 15 tetrakis(1-methylethyl) ester In another aspect, the invention provides use of an agonist of farnesoid X receptor in the manufacture of a medicament for reducing mammalian hair growth by application to an area of skin from which reduced hair is desired, a dermatologically acceptable composition comprising said agonist in an amount effective to reduce hair growth; 20 wherein the agonist is selected from the group consisting of: (i) 7-methyl-9-(3,3- dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid methyl ester (juvenile hormone III); (ii) 7-methyl-9-(3,3- dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid ethyl ester; (iii) benzenesulfonamide, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2-trifluoro-1-hydroxy-1 25 (trifluoromethyl)ethyl] phenyl]-; (iv) benzoic acid, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5-(-methylethyl)-4 isoxazolyl]methoxy]phenyl]ethenyl]-; (v) phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, tetraethyl ester; 30 (vi) phosphonic acid, [2-[3,5-bis(l,I-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetrakis(1-methylethyl) ester; (vii) phosphonic acid, [2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethylidene]bis-, tetraethyl ester; and SPEC1 (DV)_Amended pages & claims)_923469_BDJ_22.08.2011 -4B (viii) phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl]ethenylidene]bis-, tetrakis(1-methylethyl) ester. In another aspect, the invention provides a method of reducing unwanted mammalian hair growth by applying to the skin a compound selected from the group 5 consisting of bile acids, analogs of bile acids, and derivatives of bile acids. In another aspect, the invention provides a method of reducing unwanted mammalian hair growth by applying to the skin a compound selected from the group consisting of farmesoids, analogs of farnesoids, and derivatives of farnesoids. In another aspect, the invention provides a method of reducing unwanted 10 mammalian hair growth by applying to the skin a compound that increases the formation of FXR-RXR heterodimer, the expression of farnesoid X receptor, or promotes coactivator recruitment and interaction with FXR-RXR heterodimer. In a further aspect, the invention provides a method of providing a benefit to exfoliated skin by applying any of the above agonists/compounds. 15 Typically, in practicing the aforementioned methods, the agonist/ compound will be included in a topical composition along with a dermatologically or cosmetically acceptable vehicle. Accordingly, the present invention also relates to topical compositions comprising a dermatologically or cosmetically acceptable vehicle and an agonist of famesoid X receptor. The present invention further relates to topical compositions comprising a dermatologically or 20 cosmetically acceptable vehicle and (a) a SPEC (DIV)_Amnded pages & claims) 923469 BDJ 22.08.2011 WO 2006/130330 PCT/US2006/018663 compound selected from the group consisting of bile acids, analogs or derivatives of bile acids; (b) a compound selected from the group consisting of farnesoids, analogs or derivatives of farnesoids; and/or (c) a compound that increases the formation of FXR-RXR heterodimer, the expression of famesoid X receptor, or promotes coactivator 5 recruitment and interaction with FXR-RXR heterodimer. In addition, the present invention relates to the use of an agonist of farnesoid X receptor for the manufacture of a therapeutic topical composition for reducing hair growth. Further, the present invention relates to the use of a compound for the manufacture of a therapeutic topical composition for reducing hair growth, wherein the 10 compound is (a) a compound that selected from the group consisting of bile acids, analogs or derivatives of bile acids; (b) a compound selected from the group consisting of farnesoids, analogs or derivatives of famesoids; and/or (c) a compound that increases the formation of FXR-RXR heterodiner, the expression of farnesoid X receptor, or promotes coactivator recruitment and interaction with FXR-RXR heterodimer. 15 In some embodiments, the agonist/compound is not a carbonate or ester of t-difluoromethylomithine. Carbamates, esters, and other conjugates of -difluoromethylornithine are described in U.S.S.N. 10/397,132, which was filed on March 26, 2003, is owned by the same owner as the present application, and is hereby incorporated herein by reference. 20 "Agonist of farnesoid X receptor", as used herein, means a compound that activates farnesoid X receptor. An agonist that "interacts strongly" with the farnesoid X receptor is one that binds the receptor with such affinity that it elicits a response that is at least approximately comparable to (in magnitude) to that elicited by farnesoids. 25 Specific compounds include both the compound itself and pharmaco logically acceptable salts of the compound. Other features and advantages of the invention may be apparent from the detailed description and from the claims.
-6 An example of a preferred composition includes at least one agonist of farnesoid X receptor in a cosmetically and/or dermatologically acceptable vehicle. The composition may be a solid, semi-solid, or liquid. The composition may be, for example, a cosmetic and dermatologic product in the form of an, for example, ointment, lotion, foam, cream, gel, or 5 solution. The composition may also be in the form of a shaving preparation, an aftershave or an antiperspirant. The vehicle itself can be inert or it can possess cosmetic, physiological and/or pharmaceutical benefits of its own. Examples of agonists of farnesoid X receptor include bile acids, famesoids, their 10 analogs and derivatives, and other compounds. Derivatives and analogs of bile acids are described. For example, J. Med. Chem. (2004), 47, 4559-4569 describes bile acid derivatives. J. Biol. Chem. (2004), 279(10), 8856 8861. describes various bile acids. U.S. Pat. 6187814 describes farnesoid derivatives. Other 15 examples of agonists of farnesoid X receptor are disclosed in W02004007521, W003015771, W02004048349, W003076418, W02004046162, W003060078, W002072598, WO03080803, W02003086303, WO 2004046068, U.S. Pat. 20030187042, U.S. Pat. 0040176426, U.S. Pat. 20040180942, U.S. Pat. 6452032, U.S. Pat. 2003203939, U.S. Pat. 2005004165, J. med. Chem. (2000), 43(6), 2971-2974, Mol. Gen. Met. (2004), 83, 184-187, 20 Drugs for the future 91999), 24(4), 431-438, Current Pharmaceutical Design (2001), 7, 231 259. Examples of coactivators involved in FXR-RXR hetrodimer are disclosed in Genes & Dev. (2004), 18, 157-169 and J. Biol. Chem. (2004), 279(35), 36184-36191. All of these references are incorporated by reference. 25 Specific examples of agonists of farnesoid X receptor are provided in Tables I. SPECI (DN)_Amended pages & claims) 923469_RDJ_22.09201) WO 2006/130330 PCT/US2006/018663 -7 TABLE I Bxamples of Farnesoid X receptor agonists Farnesol Farnesal 5 Farnesyl acetate Farnesoic acid Methyl farnesyl ether Methyl farnesoate Ethyl farnesyl ether 1o Ethyl farnesoate 7-Methyl-9-(3,3-dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid methyl ester (also known as Juvenile hormone I) Lithocholic acid Cholic acid 15 Deoxycholic acid Chenodeoxycholic acid Ursodeoxycholic acid 6-alpha-Ethyl chenodeoxycholic acid Benzenesulfonamide, N-(2,2,2-trifluoroethyl)-N-[4-[2,2,2 20 trifLuoro-1-hydroxy-l-(trifluoromethyl)ethyl]phenyl]- (also known as T0901317) Benzoic acid, 3-[2-[2-chloro-4-[[3-(2,6-dichlorophenyl)-5 (1-methylethyl)-4- isoxazolyl]methoxy]phenyl]ethenyl]- (also known as GW4064) 25 Phosphonic acid, [[3,5-bis(l, 1 -dinethylethyl)-4-hydroxyphenyl] ethenylidene]bis-, tetraethyl ester (also known as SR-12813) Phosphonic acid, [2-13,5-bis(i,I-dimethylethyl)-4-hydroxyphenyl] ethylidene]bis-, tetrakis(1-methylethyl) ester (also known as SR-45023A or apomine) 30 Phosphonic acid, (2-[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] ethylidene]bis-, tetraethyl ester (also known as SR-9213) Phosphonic acid, [[3,5-bis(1,1-dimethylethyl)-4-hydroxyphenyl] ethenylidene]bis-, tetrakis(1-methylethyl) ester (also known as SR-12823i) WO 2006/130330 PCT/US2006/018663 7-Methyl-9-(3,3-dimethyloxivanyl)-3-methyl-2,6-nonadienoic acid ethyl ester 3, 7$-dihydroxy-6$-ethyl-5p-cholan-24-oic acid 38, 78-dihydroxy-6-propyl-5p-cholan-24-oic acid 5 38, 7-dihydroxy-6#-allyl-5p-cholan-24-oic acid The composition may include more than one agonist of farnesoid X receptor. In addition, the composition may include one or more other types of hair growth reducing agents, such as those described in U.S. Pat. No. 4,885,289; U.S. Pat. No. 4,720,489; U.S. Pat. No. 5,132,293; U.S. Pat. 5,096,911; U.S. Pat. No. 5,095,007; U.S. 10 Pat. No. 5,143,925; U.S. Pat. No. 5,328,686; U.S. Pat. No. 5,440,090; U.S. Pat. No. 5,364,885; U.S. Pat. No. 5,411,991; U.S. Pat. No. 5,648,394; U.S. Pat. No. 5,468,476; U.S. Pat. No. 5,475,763; U.S. Pat. No. 5,554,608; U.S. Pat. No. 5,674,477; U.S. Pat. No. 5,728,736; U.S. Pat. 5,652,273; WO 94/27586; WO 94/27563; and WO 98/03149, all of which are incorporated herein by reference. 15 The concentration of the agonist in the composition may be varied over a wide range up to a saturated solution, preferably from 0.1% to 30% by weight or even more; the reduction of hair growth increases as the amount of agonist applied increases per unit area of skin. The maximum amount effectively applied is limited only by the rate at which the agonist penetrates the skin. The effective amounts may range, for example, 20 from 10 to 3000 micrograms or more per square centimeter of skin. The vehicle can be inert or can possess cosmetic, physiological and/or pharmaceutical benefits of its own. Vehicles can be formulated with liquid or solid emollients, solvents, thickeners, humectants and/or powders. Bmollients include stearyl alcohol, mink oil, cetyl alcohol, oleyl alcohol, isopropyl laurate, polyethylene glycol, 25 petroleum jelly, palmitic acid, oleic acid, and myristyl myristate. Solvents include ethyl alcohol, isopropanol, acetone, diethylene glycol, ethylene glycol, dimethyl sulfoxide, and dimethyl formamide. The composition optionally can include components that enhance the penetration of the agonist into the skin and/or to the site of action. Examples of WO 2006/130330 PCT/US2006/018663 -9 penetration enhancers include urea, polyoxyethylene ethers (e.g., Brij-30 and Laureth-4), 3-hydroxy-3,7, 11 -trimethyl-1,6, 10-dodecatriene, terpenes, cis-fatty acids (e.g., oleic acid, pahnitoleic acid), acetone, laurocapram, dimethylsulfoxide, 2-pyrrolidone, oleyl alcohol, glyceryl-3-stearate, propan-2-ol, myristic acid isopropyl ester, cholesterol, and propylene 5 glycol, A penetration enhancer can be added, for example, at concentrations of 0.1% to 20% or 0.5% to 5% by weight. The composition also can be formulated to provide a reservoir within or on the surface of the skin to provide for a continual slow release of the agonist. The composition also may be formulated to evaporate slowly from the skin, allowing the 10 agonist extra time to penetrate the skin. A topical cream composition containing an agonist of farnesoid X receptor may be prepared by mixing together water and all water soluble components in a mixing vessel- A. The pH is adjusted in a desired range from about 3.5 to 8.0. In order to achieve complete dissolution of ingredients the vessel temperature may be raised to up to is 45*C. The selection of pH and temperature will depend on the stability of the agonist. The oil soluble components, except for the preservative and fragrance components, are mixed together in another container (B) and heated to up to 70*C to melt and mix the components. The heated contents of vessel B are poured into the water phase (container A) with brisk stirring. Mixing is continued for about 20 minutes. The preservative 20 components are added at temperature of about 40*C. Stirring is continued until the temperature reaches about 25*C to yield a soft cream with a viscosity of 8,000 - 12,000 cps, or a desired viscosity. The fragrance components are added at about 25*C - 30*C while the contents are still being mixed and the viscosity has not yet built up to the desired range. If it is desired to increase the viscosity of the resulting emulsion, shear can 25 be applied using a conventional homogenizer, for example a Silverson LAR homogenizer with a square hole high sheer screen. The topical composition can be fabricated by including the agonist in the water phase during formulation preparation or can be added after the formulation (vehicle) preparation has been completed. The agonist can also be added during any step of the vehicle preparation. The components of come cream 30 formulations are described in the examples below.
WO 2006/130330 PCT/US2006/018663 -10 EXAMPLE I (CREAM) INCI Name W/w (%) DI Water 61.00 - 75.00 5 Agonist of farnesoid X receptor 1.00 - 15.00 Mineral oil 1.90 Glyceryl stearate 3.60 PEG 100 stearate 3.48 Cetearyl alcohol 2.59 10 Ceteareth-20 2.13 Dimethicone, 100 ct 0.48 Lipidure PMB" 3.00 Advanced moisture complex 5.00 Stearyl alcohol 1.42 15 Preservative, fragrance and color pigment qs Total 100.00 'polyquartinium-51 (Collaborative Labs, NY); b glycerin and water and sodium PCA and urea and trehalose and polyqauternium-5 1 and sodium hyaluronate (Collaborative Labs, NY) 20 EXAMPLE 2 (CREAM) INCI Name W/w (%) Agonist of farnesoid X receptor 0.5 - 15.00 Glyceiyl (glycerin) 0-5 25 Isoceteth-20 3-7 Glyceryl isostearate 1.5 - 5 Dicaprylyl ether 3 - 15 Glyceryl triacetate (triacetin) 0.5 - 10 Preservative, fragrance and color pigment q.s.
WO 2006/130330 PCT/US2006/018663 -11 INCI Name W/w (%) Water q.s. to 100.00 EXAMPLE 3 (CREAM) INCI Name W/w (%) 5 Agonist of farnesoid X receptor 0.5 - 15.00 Glyceryl (glycerin) 0-5 Isoceteth-20 3-7 Glyceryl isostearate 1.5 - 5 Dicaprylyl ether 3 - 15 10 1-dodecyl-2-pyrrolidanone 0.5 - 10% Preservative, fragrance and color q.s. Water to 100.00 EXAMPLE 4 (CREAM) 15 INCI Name W/w (%) Water 70 Glyceryl stearate 4 PEG-100 4 Cetearyl alcohol 3 20 Ceteareth-20 2.5 Mineral oil 2 Stearyl alcohol 2 Dimethicone 0.5 Preservatives 0.43 25 1 -Dodecyl-2-pyrrolidanone 1-10 Total 100 WO 2006/130330 PCT/US2006/018663 - 12 An agonist of farnesoid X receptor is added to the Example 4 formulation and mixed until solubilized. EXAMPLE 5 (CREAM) sINCIName W/w (%) Water 70 - 80 Glyceryl stearate4 PEG-100 4 Cetearyl alcohol 3 10 Ceteareth-20 2.5 Mineral oil 2 Stearyl alcohol 2 Dimethicone 0.5 Preservatives 0.43 is Monocaprylate/Caprate (Estol 3601, Uniquema, NJ 1-10 Total 100 An agonist of farnesoid X receptor is added to the Example 5 formulation and mixed until solubilized. EXAMPLE 6 20 (CREAM) INCI Name W/w (%) Water 70- 80 Glyceryl stearate4 PBG-1004 25 Cetearyl alcohol 3 Ceteareth-20 2.5 Mineral oil 2 Stearyl alcohol 2 WO 2006/130330 PCT/US2006/018663 - 13 INCI Name W/w (%) Dimethicone 0.5 Preservatives 0.43 cis Fatty acids 1-10 Total 100 5 An agonist of farnesoid X receptor is added to the Example 6 formulation and mixed until solubilized. EXAMPLE 7 (CREAM) 1NCIName W/w (%) 10 Water 70-80% Glyceryl stearate 4 PEG-1004 Cetearyl alcohol 3 Ceteareth-20 2.5 15 Mineral oil 2 Stearyl alcohol 2 Dimethicone 0.5 Preservatives 0.43 Terpene(s) 1-10 20 Total 100 An agonist of farnesoid X receptor is added to the Example 7 formulation and mixed until solubilized. EXAMPLE 8 (CREAM) 25 INCI Name W/w (%) Water 70 - 80% Glyceryl stearate 4 WO 2006/130330 PCT/US2006/018663 - 14 INCI Name W/w(%) PEG-100 4 Cetearyl alcohol 3 Ceteareth-20 2.5 Mineral oil 2 5 Stearyl alcohol 2 Dimethicone 0.5 Preservatives 0.43 Polyoxyethylene sorbitans (tween) 1-10 Total 100 10 An agonist of farnesoid X receptor is added to the Example 8 formulation and mixed until solubilized. An agonist of farnesoid X receptor is added to the example 8 formulation and mixed until solubilized. A hydroalcoholic formulation containing an agonist of farnesoid X is receptor is prepared by mixing the formulation components in a mixing vessel. The pH of the formulation is adjusted to a desired value in the range of 3.5 - 8.0. The pH adjustment can also be made to cause complete dissolution of the formulation ingredients. In addition, heating can be applied to up to 45"C, or even up to 70*C depending on the stability of the agonist to achieve dissolution of the formulation ingredients. The 20 components of two hydroalcoholic formulations are listed below. EXAMPLE 9 (hydro-alcoholic) INCI Name w/w (%) Water 48.00 - 62.50 25 An agonist of farnesoid X receptor 0.5 -15.00 Bthanol 16.00 Propylene glycol 5.00 Dipropylene glycol 5.00 WO 2006/130330 PCT/US2006/018663 - 15 INCI Name w/w (%) Benzyl alcohol 400 Propylene carbonate 2.00 Captex-300" 5.00 Total 100.00 s "caprylic/capric triglyceride (Abitec Corp., OH). EXAMPLE 10 (hydro-alcoholic) INCI Name w/w (%) Water 53.00 -67.9 1o An agonist of farnesoid X receptor 0.1 -15.00 Ethanol 16.00 Propylene glycol 5.00 Dipropylene glycol dimethyl ether 5.00 Benzyl alcohol 4.00 15 Propylene carbonate 2.00 Total 100.00 EXAMPLE 11 (hydro-alcoholic) INCI Name w/w (%) 20 Ethanol 80 Water 17.5 Propylene glycol dipelargonate 2.0 Propylene glycol 0.5 Total 100.00 25 An agonist of farnesoid X receptor is added to the Example 11 formulation and mixed until solubilized. The composition should be applied topically to a selected area of the body WO 2006/130330 PCT/US2006/018663 -16 from which it is desired to reduce hair growth. For example, the composition can be applied to the face, particularly to the beard area of the face, i.e., the cheek, neck, upper lip, and chin. The composition also may be used as an adjunct to other methods of hair removal including shaving, waxing, mechanical epilation, chemical depilation, 5 electrolysis and laser-assisted hair removal. Other actions that make their concept appearance are concurrent skin benefits in addition to hair reduction. The composition can also be applied to the legs, arms, torso or armpits. The composition is suitable, for example, for reducing the growth of unwanted hair in women. In humans, the composition should be applied once or twice a day, or even more 10 frequently, to achieve a perceived reduction in hair growth. Perception of reduced hair growth could occur as early as 24 hours or 48 hours (for instance, between normal shaving intervals) following use or could take up to, for example, three months. Reduction in hair growth is demonstrated when, for example, the rate of hair growth is slowed, the need for removal is reduced, the subject perceives less hair on the treated site, 15 or quantitatively, when the weight of hair removed (i.e., hair mass) is reduced. Human hair follicle growth assay Human hair follicles in growth phase (anagen) were isolated from face-lift tissue (obtained from plastic surgeons) under dissecting scope using a scalpel and watchmakers forceps. The skin was sliced into thin strips exposing 2-3 rows of follicles 20 that could readily be dissected. Follicles were placed into 0.5 ml William's E medium (Life Technologies, Gaithersburg, MD.) supplemented with 2 mM L-glutamine, 10 jig/ml insulin, 10 ng/ml hydrocortisone, 100 units of penicillin, 0.1 mg/nil streptomycin and 0.25 ig/ml amphotericin B. The follicles were incubated in 24-well plates (1 follicle/well) at 37*C in an atmosphere of 5% CO 2 and 95% air. Compounds are dissolved into dimethyl 25 sulfoxide as 100-fold stock solution. The control hair follicles were treated with dimethyl sulfoxide without prostaglandin. The follicles were photographed in the 24-well plates under the dissecting scope at a power of 10X. Typically, image recordings were made on day 0 (day follicles were placed in culture), and again on day 7. The length of hair follicle was assessed using an image analysis software system. The growth of hair fiber was 30 calculated by the subtracting the follicle length on day 0 from that determined on day 7. Hamster hair mass assay Hamster hair mass was determined using a method similar to that WO 2006/130330 PCT/US2006/018663 - 17 described in previous patent (US2004/0198821). The agonists of famesoid X receptor demonstrated a significant reduction of human hair follicle growth. All of the six agonists of farnesoid X receptor tested significantly reduced hair growth. The results are provided in Table II. The hair growth 5 inhibition profile by the agonists of famnesoid X receptor was found to be dose-dependent. The results are provided in Table III. TABLE II Inhibition of human hair follicle growth by the agonists of famnestoid X receptor Dose Hair follicle length increase (m) 10 FXR agonists _ (pM) Treated Control % Inhibition Deoxycholic acid 100 0.06t0.05 1.07 ± 0.14 94.3 t 4.7 Ursodeoxycholic acid 200 0.20± 0.11 1.07 10.14 81.3 10.3 Chenodeoxycholic acid 100 0.05 ±0.06 1.07 ± 0.14 95.3 5.6 Lithocholic acid 50 0.02 +0.02 1.07:E 0.14 98.1 ± 1.9 15 Farnesol 100 0.04±0.07 0.87± 0.23 95.4 8.0 Juvenile hormone III 100 0.21±0.15 0.87± 0.23 75.9117.2 TABLE m Dose-dependent reduction of human hair follicle growth by the agonists of farnestold X receptor Dose Growth of follicle (mm) 20 FXR agonists (pM) Treated Control % Reduction Deoxycholic acid 10 1.20± 0.49 1.76 0.36 31.8 * 18.1 50 0.54L t0.34 1.76± 0.36 69.3±13.6 100 0.54 ± 0.34 1.76 * 0.36 69.3 * 13.6 Ursodeoxycholic acid 50 1.12*0.24 1.76± 0.36 36.3 13.6 100 0.86 ± 0.20 1.76 t0.36 51.1 ± 11.4 150 0.61 ± 0.20 1.76± 0.36 65.3 & 11.4 Chenodeoxycholic acid 5 1.53 t 0.29 1.55 t 0.02 1.3 ± 18.7 25 0.79-&0.27 1.55 0.02 49.0± 17.4 50 0.13±0.10 1.55± 0.02 91.6 * 6.5 Lithocholicacid 2 0.82 ±0.14 1.24 ±0.23 33.9±11.3 10 0.44± 0.16 1.24 0.23 64.5 12.9 _20 0.03 ± 0.06 1.24 t 0.23 97.6 ±4.8 25 Furthermore, the agonists of farnestoid X receptor were tested in the hamster hair mass assay. The agonists reduced hair mass in vivo as shown in Table IV.
WO 2006/130330 PCT/US2006/018663 - 18 TABLE IV Reduction of hamster hair mass by the agonists of farnestold X receptor Dose Hair mass g) FXR agonists (w/v) Vehicle' Treated Control % Inhibition Lithocholic acid 4% ethanol 1.01 ± 0.12 1.96 +0.19 46.4 h 6.0 5 Chenodeoxycholic acid 5% ethanol 0.54 ± 0.08 2.28 t 0.19 76.4 ± 2.6 Deoxycholic acid 5% ethanol 0.92 + 0.14 2.66 1 0.28 63.6 :16.0 Ursodeoxycholic acid 5% ethanol 1.02 A 0.16 2.43 ± 0.31 56.8 ± 3.8 *The vehicle contains 90% ethanol and 10% propylene glycol. Accordingly, other embodiments are within the scope of the following 10 claims.